| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = -$2 ) |
| | 2024 | 2021 | DAHLIA BIOSCIENCES, INC. | 21 TARABROOK DR | ORINDA | CA | 94563-3120 | CONTRA COSTA | USA | R41AI157717 | Multiplexed CRISPR-based immune cell RNA profiling by flow and mass cytometry | 000 | 1 | NIH | 10/23/2023 | -$2 |
|
| Issue Date FY: 2023 ( Subtotal = -$48 ) |
| | 2023 | 2020 | DAHLIA BIOSCIENCES, INC. | 21 TARABROOK DR | ORINDA | CA | 94563-3120 | CONTRA COSTA | USA | R41HG011224 | Sorting live cells using RNA-targeting CRISPR-Cas9 (RCas9) | 000 | 1 | NIH | 5/10/2023 | -$48 |
|
| Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2020 | DAHLIA BIOSCIENCES, INC. | 21 TARABROOK DR | ORINDA | CA | 94563-3120 | CONTRA COSTA | USA | R41HG011224 | Sorting live cells using RNA-targeting CRISPR-Cas9 (RCas9) | 000 | 1 | NIH | 1/12/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $299,978 ) |
| | 2021 | 2021 | DAHLIA BIOSCIENCES, INC. | 21 TARABROOK DR | ORINDA | CA | 94563-3120 | CONTRA COSTA | USA | R41AI157717 | Multiplexed CRISPR-based immune cell RNA profiling by flow and mass cytometry | 000 | 1 | NIH | 12/1/2020 | $299,978 |
|
| Issue Date FY: 2020 ( Subtotal = $299,128 ) |
| | 2020 | 2020 | DAHLIA BIOSCIENCES, INC. | 21 TARABROOK DR | ORINDA | CA | 94563-3120 | CONTRA COSTA | USA | R41HG011224 | Sorting live cells using RNA-targeting CRISPR-Cas9 (RCas9) | 000 | 1 | NIH | 4/3/2020 | $299,128 |
|
|
